BENITIONSClinical Trial Intelligence

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease

2期 已完成 NCT06350123

适应症Chronic Kidney Disease
分期2期
申办方AstraZeneca
状态已完成
受试者人数324 人
干预(药物)Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
开始日期2024年5月1日
完成日期2025年5月9日
结果公布日2026年6月26日

摘要

The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effect of the balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD.

Relative Change in Urine Albumin-to-Creatinine Ratio (UACR) From Baseline to Week 12

Baseline (Day 1) until Week 12 (Day 85) · mg/g

Balcinrenone/Dapagliflozin 15 mg/10 mg0.76 mg/g
Balcinrenone/Dapagliflozin 40 mg/10 mg0.66 mg/g
Dapagliflozin 10 mg0.98 mg/g
p-value<0.001
Percent change difference-32.77 (95% CI -41.96–-22.14)

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。